FRANKLIN, Tenn. / Mar 02, 2023 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two investor conferences in March.
On Tuesday, March 7, 2023, the Company will participate in the Raymond James 44th Annual Institutional Investors Conference, which is being held March 5 - 8, 2023, in Orlando, Florida. The Company’s presentation will be at 6:30 a.m. Central Time/7:30 a.m. Eastern Time.
On Wednesday, March 8, 2023, the Company will participate in the Cowen 43rd Annual Health Care Conference, to be held March 6 - 8, 2023, in Boston, Massachusetts. The Company’s presentation will be at 9:30 a.m. Central Time/10:30 a.m. Eastern Time.
The live webcast of both presentations will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentation will also be available on the Company’s website for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of December 31, 2022, Acadia operated a network of 250 behavioral healthcare facilities with approximately 11,000 beds in 39 states and Puerto Rico. With approximately 23,000 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Last Trade: | US$23.84 |
Daily Change: | -4.85 -16.90 |
Daily Volume: | 3,865,351 |
Market Cap: | US$2.210B |
February 27, 2025 October 30, 2024 July 31, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load